Wexford Capital’s Neurocrine Biosciences NBIX Stock Holding History

Wexford Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,089	Closed	-$120K	–	294
2025 Q1	$120K	Buy	+1,089	New	+$138K	0.03%	195
2017 Q3	–	Sell	-7,800	Closed	-$359K	–	178
2017 Q2	$359K	Buy	+7,800	New	+$378K	0.03%	131
2016 Q3	–	Sell	-27,020	Closed	-$1.23M	–	179
2016 Q2	$1.23M	Hold	27,020	–	–	0.21%	67
2016 Q1	$1.07M	Buy	+27,020	New	+$1.07M	0.21%	72

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wexford Capital's NBIX Position: Q2 2025 in Review

Wexford Capital sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 1,089 shares — an estimated $120K sold.

Wexford Capital first reported a position in NBIX in Q1 2016 and held it in 4 quarters. The position peaked at $1.23M in Q2 2016. 587 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

Wexford Capital reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
Wexford Capital sold 1,089 Neurocrine Biosciences shares in Q2 2025, an estimated $120K.
Wexford Capital first reported a position in Neurocrine Biosciences in Q1 2016 and held it in 4 quarters.
Wexford Capital's Neurocrine Biosciences position peaked at $1.23M in Q2 2016.
587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.